Will CRISPR-Cas9 Have Cards to Play Against Cancer? An Update on its Applications

Daisy, P.; Shreyas, Kuduvalli S.; Anitha, T. S.

doi:10.1007/s12033-020-00289-1

Cited by 5 publications

(2 citation statements)

References 146 publications

(103 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 94 CRISPR-Cas9 has also shown great potential in the treatment of cancer, including HCC. 95 , 96 Wang et al reported that the knockout of CXC chemokine receptor 4 (CXCR4), associated with a poor prognosis in HCC, by CRISPR/Cas9 not only suppresses proliferation and invasion but also increases sensitivity to the anticancer drug cisplatin in HCC. 97 Another study has shown that the CRISPR/Cas9-mediated knockout of nuclear receptor binding SET domain-containing protein 1 inhibits the ability of HCC cells to proliferate and migrate.…”

Section: Overview Of Hcc Therapy Targeting Bmi1mentioning

confidence: 99%

Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma

Wang

Fan

Sun

et al. 2022

Technol Cancer Res Treat

View full text Add to dashboard Cite

Liver cancer has high rates of morbidity and mortality, and its treatment is a global health challenge. Hepatocellular carcinoma (HCC) accounts for 90% of all primary liver cancer cases. B-lymphoma Mo-MLV insertion region 1 ( BMI1) has been identified as a proto-oncogene, which contributes to the initiation and progression of many malignant tumors. BMI1 expression is upregulated in HCC, and it influences the occurrence and development of HCC by various mechanisms, such as the INK4a/ARF locus, NF-κB signaling pathway, and PTEN/PI3K/AKT signaling pathway. In addition, the expression of BMI1 is related to prognosis and recurrence of HCC. Hence, there is clear evidence that BMI1 is a novel and valid therapeutic target for HCC. Accordingly, the development of therapeutic strategies targeting BMI1 has been a focus of recent research, providing new directions for HCC treatment. This review summarizes the role of BMI1 in the occurrence and treatment of HCC, which will provide a basis for using BMI1 as a potential target for the development of therapeutic strategies for HCC.

show abstract

Section: Overview Of Hcc Therapy Targeting Bmi1mentioning

confidence: 99%

Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma

Wang

Fan

Sun

et al. 2022

Technol Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…7 CRISPR-related protein 9 (Cas9) uses the CRISPR sequence as a guide to recognize and cut a specific strand of DNA that is complementary to the CRISPR sequence. 8 Due to their ability to remove specific genes, CRISPR-Cas9 can be used in a variety of biological applications for research and therapeutic purposes. [9][10][11][12][13][14] Stem cells are undifferentiated cells found in embryonic and adult tissues.…”

Section: Introductionmentioning

confidence: 99%